دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Specialists and generalists in skin disease management: educational, clinical and research imperatives
P.J. Magin,E.T.V. Tng
doi : 10.1111/bjd.20575
Volume 186, Issue 1 p. 1-2
British Association of Dermatologist guidelines: a lighthouse to help guide clinicians and researchers planning future clinical trials for vitiligo
K. Ezzedine,A.G. Pandya
doi : 10.1111/bjd.20815
Volume 186, Issue 1 p. 3-4
Risankizumab vs. fumaric acid esters: a direct comparison
P. Fleming
doi : 10.1111/bjd.20813
Volume 186, Issue 1 p. 4-5
How important is it to distinguish between eczema and atopic dermatitis in infants? Implications for prognosis and epidemiological research
Z. Chiesa
doi : 10.1111/bjd.20814
Volume 186, Issue 1 p. 6
Administrative data and scientific evidence: a lesson from France – the safety of systemic treatment for psoriasis during the COVID-19 pandemic
S. Cazzaniga,L. Naldi
doi : 10.1111/bjd.20776
Volume 186, Issue 1 p. 7-8
Concerns have repeatedly been raised about the safety of systemic treatment for immune-related conditions during the COVID-19 pandemic.1 Regarding psoriasis, reassuring data on the risk of hospitalization and mortality due to SARS-CoV-2 infection have so far been provided for patients on systemic treatment,2-4 with some papers even suggesting a protective effect of biological treatment for the most ominous outcomes.5 As a matter of fact, most of the available studies were published under the pressure to provide some kind of evidence, and were either underpowered or suffered from important methodological flaws, such as the lack of appropriate denominators, making their estimates questionable.6, 7 There is a need to develop reliable monitoring systems on a large scale at sustainable costs.
Benefits of a nationwide population-based skin cancer screening programme – still a controversial debate
T. Eigentler
doi : 10.1111/bjd.20709
Volume 186, Issue 1 p. 8-9
Since its introduction in 2008, the nationwide population-based skin cancer screening programme in Germany has faced a number of critical arguments, which in the end focused on the fact that no reduction in skin cancer-associated mortality has been observed.1, 2
The expected missing heritability of hidradenitis suppurativa in perspective
K.R. van Straalen,W. Gulliver
doi : 10.1111/bjd.20803
Volume 186, Issue 1 p. 9-10
The ‘Chronic Itch Burden Scale’: giving patients with chronic pruritus a voice
M. Gabes
doi : 10.1111/bjd.20714
Volume 186, Issue 1 p. 10-11
More than a quarter of all people experience the burden of chronic pruritus (CP) during their lives.1 Undoubtedly, CP negatively affects patients’ health-related quality of life (HRQoL).2 It may be perceived as disturbing during everyday activities, when sleeping and it may also affect how the patient is feeling. With various levels of severity, CP has more or less burdensome consequences for the patients and their functioning. For some individuals, scratching their skin is also embarrassing (itch–scratch cycle).
The critical need for patient-reported outcome measures to assess the severity and impact of systemic sclerosis
M. Hughes,C.P. Denton
doi : 10.1111/bjd.20777
Volume 186, Issue 1 p. 11-12
Do the gut and skin microbiomes share thoughts on melanoma development?
N.O.S. Camara
doi : 10.1111/bjd.20811
Volume 186, Issue 1 p. 12-13
Melanoma metastasis, BRAF mutation and GJB5 connexin expression: a new prognostic factor
J.E. Fromme,P. Zigrino
doi : 10.1111/bjd.20756
Volume 186, Issue 1 p. 13-14
Metastatic melanoma is one of the deadliest cancers, harbouring several mutations with the major ones occurring in the BRAF, NRAS and NF1 genes.1 About 60% of patients display the BRAF V600E mutation, leading to constitutive activation of the mitogen-activated protein kinase (MAPK) pathway, which drives tumour growth.2 Although melanoma was previously considered untreatable, the development of inhibitors of mutated BRAF signalled a change in the fight against melanoma, eliciting response rates of around 76%.3
Prevention of chemotherapy-induced hair loss by peroxisome proliferator-activated receptor-? modulation
K. Natsuga
doi : 10.1111/bjd.20806
Volume 186, Issue 1 p. 14-15
COVID-19 vaccines and skin manifestations
V. Bataille,S. Puig
doi : 10.1111/bjd.20807
Volume 186, Issue 1 p. 15-15
It has been a busy time for dermatologists, as SARS-CoV-2 has caused common and diversified skin reactions that may be the only sign of infection. Furthermore, skin changes and symptoms are also being seen after COVID-19 vaccinations. In this issue of the BJD, the multicentre study by Català et al., which examines cutaneous side-effects of COVID-19 vaccines, demonstrates several novel features.1 Firstly, this study shows that multicentre studies can be set up rapidly via the use of electronic case report forms (eCRFs) rather than old-fashioned paper entries. It is impressive that so many dermatologists from all over Spain participated in this study and broad questionnaires covered many potential associations.
Mogamulizumab-associated rash (MAR) mars its efficacy in the treatment of cutaneous lymphoma
G. Blanchard,E. Guenova
doi : 10.1111/bjd.20821
Volume 186, Issue 1 p. 15-16
Skin adnexal tumours in a tertiary dermatopathology service
Z. Maruši?,E. Calonje
doi : 10.1111/bjd.20816
Volume 186, Issue 1 p. 16-17
British Association of Dermatologists guidelines for the management of people with vitiligo 2021*
V. Eleftheriadou,R. Atkar,J. Batchelor,B. McDonald,L. Novakovic,J.V. Patel,J. Ravenscroft,E. Rush,D. Shah,R. Shah,L. Shaw,A.R. Thompson,M. Hashme,L.S. Exton,M.F. Mohd Mustapa,L. Manounah,the British Association of Dermatologists’ Clinical Standards Unit
doi : 10.1111/bjd.20596
Volume 186, Issue 1 p. 18-29
The overall objective of the guideline is to provide up-to-date, evidence-based recommendations for the management of vitiligo.
Direct comparison of risankizumab and fumaric acid esters in systemic therapy–naïve patients with moderate-to-severe plaque psoriasis: a randomized controlled trial*
D. Thaçi,K. Eyerich,A. Pinter,M. Sebastian,K. Unnebrink,S. Rubant,D. A. Williams,P. Weisenseel
doi : 10.1111/bjd.20481
Volume 186, Issue 1 p. 30-39
Difamilast, a selective phosphodiesterase 4 inhibitor, ointment in paediatric patients with atopic dermatitis: a phase III randomized double-blind, vehicle-controlled trial*
H. Saeki,N. Baba,K. Ito,D. Yokota,H. Tsubouchi
doi : 10.1111/bjd.20655
Volume 186, Issue 1 p. 40-49
Diagnosing atopic dermatitis in infancy using established diagnostic criteria: a cohort study*
K.M.A. Endre,L. Landrø,M. LeBlanc,P. Gjersvik,K.C. Lødrup Carlsen,G. Haugen,G. Hedlin,C.M. Jonassen,B. Nordlund,K. Rudi,H.O. Skjerven,A.C. Staff,C. Söderhäll,R. Vettukattil,E.M. Rehbinder
doi : 10.1111/bjd.19831
Volume 186, Issue 1 p. 50-58
Psoriasis-related treatment exposure and hospitalization or in-hospital mortality due to COVID-19 during the first and second wave of the pandemic: cohort study of 1?326?312 patients in France*
L. Penso,R. Dray-Spira,A. Weill,M. Zureik,E. Sbidian
doi : 10.1111/bjd.20659
Volume 186, Issue 1 p. 59-68
Are patients benefiting from participation in the German skin cancer screening programme? A large cohort study based on administrative data*
T. Datzmann,O. Schoffer,F. Meier,A. Seidler,J. Schmitt
doi : 10.1111/bjd.20658
Volume 186, Issue 1 p. 69-77
Evidence of gene–gene interaction in hidradenitis suppurativa: a nationwide registry study of Danish twins
R. Kjærsgaard Andersen,S.B. Clemmensen,L.A. Larsen,J.v.B. Hjelmborg,N. Ødum,G.B.E. Jemec,K. Christensen
doi : 10.1111/bjd.20654
Volume 186, Issue 1 p. 78-85
Development and preliminary validation of the patient-reported Chronic Itch Burden Scale assessing health-related quality of life in chronic pruritus
J. Theunis,C. Nordon,B. Falissard,M. Orri,V. Mengeaud,L. Misery
doi : 10.1111/bjd.20582
Volume 186, Issue 1 p. 86-95
Development and validation of a patient-reported outcome in systemic sclerosis: the Hand scleroDerma lived Experience (HAnDE) scale*
J. Sibeoni,B. Dunogué,A. Dupont,D. Haiddar,N. Benmostefa,B. Falissard,L. Mouthon,A. Révah-Levy,L. Verneuil
doi : 10.1111/bjd.20688
Volume 186, Issue 1 p. 96-105
Early melanoma invasivity correlates with gut fungal and bacterial profiles*
F. Vitali,R. Colucci,M. Di Paola,M. Pindo,C. De Filippo,S. Moretti,D. Cavalieri
doi : 10.1111/bjd.20626
Volume 186, Issue 1 p. 106-116
GJB5 association with BRAF mutation and survival in cutaneous malignant melanoma*
M. Scatolini,A. Patel,E. Grosso,M. Mello-Grand,P. Ostano,R. Coppo,M. Vitiello,T. Venesio,A. Zaccagna,A. Pisacane,I. Sarotto,D. Taverna,L. Poliseno,D. Bergamaschi,G. Chiorino
doi : 10.1111/bjd.20629
Volume 186, Issue 1 p. 117-128
Peroxisome proliferator-activated receptor-? signalling protects hair follicle stem cells from chemotherapy-induced apoptosis and epithelial–mesenchymal transition*
I. Piccini,L. Brunken,J. Chéret,S. Ghatak,Y. Ramot,M. Alam,T.S. Purba,J. Hardman,H. Erdmann,F. Jimenez,R. Paus,M. Bertolini
doi : 10.1111/bjd.20745
Volume 186, Issue 1 p. 129-141
Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases*
A. Català,C. Muñoz-Santos,C. Galván-Casas,M. Roncero Riesco,D. Revilla Nebreda,A. Solá-Truyols,P. Giavedoni,M. Llamas-Velasco,C. González-Cruz,X. Cubiró,R. Ruíz-Villaverde,S. Gómez-Armayones,M.P. Gil Mateo,D. Pesqué,O. Marcantonio,D. Fernández-Nieto,J. Romaní,N. Iglesias Pena,L. Carnero Gonzalez,J. Tercedor-Sanchez,G. Carretero,T. Masat-Ticó,P. Rodríguez-Jiménez,A.M. Gimenez-Arnau,M. Utrera-Busquets,E. Vargas Laguna,A.G. Angulo Menéndez,E. San Juan Lasser,M. Iglesias-Sancho,L. Alonso Naranjo,I. Hiltun,E. Cutillas Marco,I. Polimon Olabarrieta,S. Marinero Escobedo,X. García-Navarro,M.J. Calderón Gutiérrez,G. Baeza-Hernández,L. Bou Camps,T. Toledo-Pastrana,A. Guilabert
doi : 10.1111/bjd.20639
Volume 186, Issue 1 p. 142-152
Mogamulizumab efficacy is underscored by its associated rash that mimics cutaneous T-cell lymphoma: a retrospective single-centre case series*
N.A. Trum,J. Zain,X.U. Martinez,V. Parekh,M. Afkhami,F. Abdulla,K.R. Carson,S.T. Rosen,C.L. Bennett,C. Querfeld
doi : 10.1111/bjd.20708
Volume 186, Issue 1 p. 153-166
A 5-year retrospective review of skin adnexal tumours received at a tertiary dermatopathology service: implications for linked genetic diagnoses*
S. Cook,D. Bajwa,L. Hollestein,A. Husain,N. Rajan
doi : 10.1111/bjd.20701
Volume 186, Issue 1 p. 167-173
Intent vs. impact: calling time on outdated phenotypic labels in dermatology
I.M. Winship,D Bajwa,N. Rajan
doi : 10.1111/bjd.20664
Volume 186, Issue 1 p. 174-175
The etiquette of hijab: recommendations to improve care in dermatology clinics
R. Rehman,A. Chabaan,I. Hamzavi,F. Fahs,T.F. Mohammad
doi : 10.1111/bjd.20665
Volume 186, Issue 1 p. 176-177
The WHO ICD-11 Classification of Dermatological Diseases: a new comprehensive online skin disease taxonomy designed by and for dermatologists
J.M.L. White,H. Lui,C.G. Chute,R. Jakob,R.J.G. Chalmers
doi : 10.1111/bjd.20656
Volume 186, Issue 1 p. 178-179
Embracing artificial intelligence: how can we make it inclusive and relevant for real-world dermatological practice?
R.N. Matin
doi : 10.1111/bjd.20699
Volume 186, Issue 1 p. 180-182
Clinical translation of hidradenitis suppurativa genetic studies requires global collaboration
A.J. Jabbour,K.R. van Straalen,A. Colvin,E.P. Prens,L. Petukhova
doi : 10.1111/bjd.20749
Volume 186, Issue 1 p. 183-185
New insights on ocular surface disease in patients with atopic dermatitis treated with dupilumab
P. Bortoluzzi,S. Ferrucci,D. Galimberti,F. Garavelli,F. Pozzo Giuffrida,A. Pizzati,A.V. Marzano,C. Mapelli
doi : 10.1111/bjd.20706
Volume 186, Issue 1 p. 186-187
‘Not relevant’ responses in the era of COVID-19: are we underestimating Dermatology Life Quality Index values?
N. Kearney,R. Hambly,A. Alsharqi,B. Kirby
doi : 10.1111/bjd.20705
Volume 186, Issue 1 p. 187-189
Since March 2020, the UK and Ireland have entered a series of lockdowns in the wake of the coronavirus pandemic with restrictions resulting in the closure of nonessential retail, hospitality and sports with employees encouraged to work from home. In this retrospective study we have demonstrated a significant decrease in DLQI values, increase in the number of ‘not relevant’ responses (NRRs) in the DLQI and change between DLQI and the modified DLQI-R during the pandemic. Given the restrictions imposed on our patients, it is important for clinicians to identify the number of NRRs in the DLQI and acknowledge the potential effect on treatment decisions and data collection for disease registries and clinical trials during the pandemic.
A national audit of oral propranolol for the treatment of infantile haemangiomas
C. Cotter,L. Solman,C. Flohr
doi : 10.1111/bjd.20738
Volume 186, Issue 1 p. 189-191
More than skin deep: a survey of real-life experiences of acne vulgaris
A.G. Ra,B. Ho,L. Bickerstaffe,A. Bewley
doi : 10.1111/bjd.20737
Volume 186, Issue 1 p. 191-193
Revealing novel, latent subsets of patients with morphoea through principal component analysis
L.F. Abbas,A.K. Joseph,S. Prasad,J.L. Zhu,K.S. Fitch,R. Haley,K.S. Torok,H.T. Jacobe
doi : 10.1111/bjd.20748
Volume 186, Issue 1 p. 193-195
Clinical characteristics of male frontal fibrosing alopecia: a single-centre case series from London, UK
T. Rayinda,S.M. McSweeney,N. Dand,D.A. Fenton,J.A. McGrath,C. Tziotzios
doi : 10.1111/bjd.20742
Volume 186, Issue 1 p. 195-197
A retrospective case series of paediatric Stevens–Johnson syndrome and toxic epidermal necrolysis: evaluation of practice using the British Association of Dermatology’s National Guidelines for children and young people
J. Forsyth,E. Russell,T. McPherson
doi : 10.1111/bjd.20741
Volume 186, Issue 1 p. 197-198
A case of COVID-19 vaccination-associated forme fruste purpura fulminans
J. Griss,S. Eichinger,S. Winkler,W. Weninger,P. Petzelbauer
doi : 10.1111/bjd.20744
Volume 186, Issue 1 p. e1-e1
We report the case of a female, 77 year old patient with multi-localized skin infarctions following vaccination with mRNA-1273 (Moderna). This phenomenon is to our knowledge otherwise only seen in infection-associated purpura fulminans - which was thoroughly ruled out in our patient. This report demonstrates that we need to be vigilant of a wider array of vascular phenomena related to Covid vaccinations.
Psoriasis: From Gene to Clinic, 9th International Congress The Queen Elizabeth II Conference Centre, London, UK 9th-11th December 2021
doi : 10.1111/bjd.20820
Volume 186, Issue 1 p. e2-e56
Changes in the expression of a junctional protein are associated with mutational status of BRAF and survival in melanoma
doi : 10.1111/bjd.20841
Volume 186, Issue 1 p. e57-e57
Melanoma is a serious form of skin cancer that arises when pigment cells in the skin (melanocytes) become malignant (cancerous). During their lifetime melanoma develops in about 1 in 40 people in the UK. Melanoma can spread to other parts of the body (i.e. ‘metastasize’), and metastatic melanoma is one of the deadliest cancers. Several mutations (faults in genetic code) have been found in metastatic melanoma including the BRAF mutation. The development of a type of treatment using inhibitors of mutated BRAF have signalled a positive step in the fight against melanoma, with encouraging response rates. However, due to the development of resistance to such therapies, the search for additional combination treatments and new biomarkers to help predict which patients will respond to different treatments remains a challenge.
Microbes in the gut relate to melanoma severity
doi : 10.1111/bjd.20842
Volume 186, Issue 1 p. e58-e58
Melanoma is a skin cancer arising from melanocytes (the cells producing melanin, a pigment determining the colour of our skin that is able to protect us against ultraviolet radiation damage). It is a serious type of cancer, causing the greatest number of skin cancer-related deaths worldwide.
Greater understanding about hair loss caused by chemotherapy
doi : 10.1111/bjd.20843
Volume 186, Issue 1 p. e59-e59
One of the more severe and most-feared side-effects of chemotherapy is hair loss, which can significantly affect the quality of life of patients undergoing these treatments. Sometimes, this can even lead to rejection of treatment by patients, especially women. Luckily, in almost all patients, the hair regrows within 3 months of stopping treatment. However, in some patients, hair loss can be permanent and this can result in substantial distress. Unfortunately, there are no established treatments to prevent or restore hair growth in these patients.
A comparison of risankizumab with fumaric acid esters for treating psoriasis
doi : 10.1111/bjd.20844
Volume 186, Issue 1 p. e60-e60
Patients with moderate to severe psoriasis that has failed to be controlled by topical therapy (applied directly to the skin) or ultraviolet light often require more intensive treatment. One such treatment is the oral drug fumaric acid esters (FAEs), which has been in use for at least 30 years, especially in Germany. A range of injectable drugs (‘biologics') have been developed more recently that target particular molecules involved in psoriasis inflammation. One of these is risankizumab (Skyrizi®) that targets interleukin 23.
Diagnosing atopic dermatitis in the first year of life
doi : 10.1111/bjd.20845
Volume 186, Issue 1 p. e61-e61
Atopic dermatitis is a common skin disease, often starting in the first year of life. However, the disease may be difficult to diagnose during infancy, even when using well-defined diagnostic criteria. Atopic dermatitis is also known as atopic eczema. The two terms are often used interchangeably in daily clinical practice, although eczema used alone is usually considered to be a more general term. In children, a diagnosis of atopic dermatitis is thought to mean a worse outcome compared with a diagnosis of eczema.
Guidelines on managing people with vitiligo
doi : 10.1111/bjd.20846
Volume 186, Issue 1 p. e62-e62
Vitiligo is a common, long-term skin condition. It affects approximatively 1% of the world’s population, regardless of age, sex or race. The type of vitiligo and its stability help indicate the chance of improvement (or chance of relapse).
Do patients benefit from participating in the German skin cancer screening programme?
doi : 10.1111/bjd.20847
Volume 186, Issue 1 p. e63-e63
The German skin cancer screening programme began in 2008 with the aim of reducing deaths from skin cancer by detecting skin cancers early, when they are more easily treated. More than 10 years after its launch, the benefits and risks of the programme are still unclear.
A scale to assess the global impact of hand involvement of patients with systemic sclerosis
doi : 10.1111/bjd.20848
Volume 186, Issue 1 p. e64-e64
Systemic sclerosis (or scleroderma) is an autoimmune disease (in which the body’s immune system begins to target its own cells and tissues) potentially affecting multiple organ systems including the skin, lungs, gastrointestinal tract and cardiovascular system. Hand involvement is central in this chronic disease and has a severe impact on patients’ quality of life. As hand involvement is a major cause of pain and disability it is therefore necessary to develop relevant tools to assess this impact. Symptoms may include cold, numb and painful fingers, skin tightening, aching joints, ulcers and swollen hands.
The effect of difamilast ointment on atopic dermatitis in Japanese children
doi : 10.1111/bjd.20849
Volume 186, Issue 1 p. e65-e65
Atopic dermatitis (AD also known as ‘eczema’) is a chronic skin disease that mainly causes itch and blistering. It is most common in children and has many negative consequences. Topical therapies (that are applied to the skin) are the main treatment for AD but are limited. New safe and effective treatments are therefore needed. One new treatment, difamilast, acts on an important part of the inflammation that causes AD.
A 5-year study of skin adnexal tumours in a large teaching hospital with implications for linked genetic diagnoses
doi : 10.1111/bjd.20850
Volume 186, Issue 1 p. e66-e66
Skin adnexal tumours (SATs) are a rare type of tumour (abnormal growth) found in children and adults. SATs of different types may develop from hair follicles, sebaceous glands or sweat glands. It is often difficult to diagnosis SATs. Certain types of these growths may also be linked to an underlying genetic (inherited) condition, some of which carry an increased risk of cancer in other parts of the body such as the bowel or kidney. Under a microscope, a skin biopsy (where a small section of tissue is removed for testing) can be examined and SATs diagnosed by skin pathology experts. We wanted to look at the types of SATs found, and to look for ways to identify patients with linked genetic diagnosis better.
Do treatments for psoriasis increase the risk of hospital admission or death caused by COVID-19 infections?
doi : 10.1111/bjd.20851
Volume 186, Issue 1 p. e67-e67
One of the difficult dilemmas facing doctors treating patients with psoriasis during the COVID-19 pandemic has been whether to continue treatments for the disease that potentially may reduce the patient’s resistance to infection. In this study from France the investigating team compared the risk (chance) of admissions to hospital and death among patients with psoriasis receiving different types of treatment for psoriasis compared with patients with psoriasis who were not receiving treatment.
A drug rash that can mimic the very cancer the drug treats
doi : 10.1111/bjd.20852
Volume 186, Issue 1 p. e68-e68
Cutaneous T-cell lymphoma (CTCL) are a rare group of cancers that develop in the skin from T cells (a type of white blood cell). Mogamulizumab is a promising treatment for CTCL, but its most common adverse effect is a drug rash named mogamulizumab-associated rash (MAR). MAR remains poorly described, and it is difficult to tell apart from CTCL itself. In this study, we reviewed past records and followed up with all 24 patients with CTCL who were treated with mogamulizumab since it was approved for use in 2018 and seen by our institution in the USA.
Varied skin reactions after COVID-19 vaccination
doi : 10.1111/bjd.20853
Volume 186, Issue 1 p. e69-e69
COVID-19 vaccination has been associated with skin reactions in clinical trials. The most frequent was the so-called ‘COVID arm’, consisting of redness, swelling and pain at the injection site in the arm. After approval and during mass vaccination, other rashes beyond the injection site have been reported but have been poorly described.
??????????????? BRAF ??????????
doi : 10.1111/bjd.20854
Volume 186, Issue 1 p. e70-e70
?????????????, ????????? (????) ???? (??) ?????????????, ? 40 ???? 1 ?????????????????????? (?“??”) , ???????????????????????????????? (????????) , ???? BRAF ??????? BRAF ?????????????????????????, ??????????, ????????????, ?????????????????????????????????????????
??????????????????
doi : 10.1111/bjd.20855
Volume 186, Issue 1 p. e71-e71
?????????????????? (??????????, ????????????, ???????????????) ??????????, ???????????????????
?????????????
doi : 10.1111/bjd.20856
Volume 186, Issue 1 p. e72-e72
????????????????????, ??????????????????????, ???????? (???????) ???????????, ????????, ????????? 3 ??????????, ??????, ?????????, ?????????????????, ???????????????????????????
Risankizumab ?????????????
doi : 10.1111/bjd.20857
Volume 186, Issue 1 p. e73-e73
???? (???????) ?????????????????????????????????????????????? (FAE), ????? 30 ?, ?????????????????????????, ??????????? (“????”) ?????????? 23 ???? Risankizumab (Skyrizi®)?
??????????????
doi : 10.1111/bjd.20858
Volume 186, Issue 1 p. e74-e74
??????????????, ??????????????, ?????????????, ????????????????????????????????????????????????, ???????“??”???????????????????, ???????, ?????????????????????
?????????
doi : 10.1111/bjd.20859
Volume 186, Issue 1 p. e75-e75
????????????????????? 1% ??????????, ?????????????????????????????????? (??????) ?
????????????????????
doi : 10.1111/bjd.20860
Volume 186, Issue 1 p. e76-e76
?????????? 2008 ???, ?????????????????????, ???????????????????? 10 ?, ?????????????
??????????????????????
doi : 10.1111/bjd.20861
Volume 186, Issue 1 p. e77-e77
?????? (????) ?????????? (?????????????????) , ??????????, ???????????????????????????????, ??????????????????????????????, ??????????????????????????????????????????????????????
Difamilast ???????????????
doi : 10.1111/bjd.20862
Volume 186, Issue 1 p. e78-e78
????? (AD, ???“??”) ????????, ????????????????????, ????????????? (?????) ??? AD ?????, ????????, ??????????????Difamilast ???????, ????? AD ?????????
?????????????? 5 ??????????, ????????????
doi : 10.1111/bjd.20863
Volume 186, Issue 1 p. e79-e79
??????? (SAT) ???????????????????? (????) ????? SAT ??????????????SAT ?????????????????????????? (??) ????, ?????????????????????????????????????????????? (??????????) ?????? SAT???????????? SAT ??, ??????????????????????
???????????????????????????
doi : 10.1111/bjd.20864
Volume 186, Issue 1 p. e80-e80
?????????, ??????????????????, ????????????????????????????????, ???????????????????????????????????????????? (??) ?
????????????????
doi : 10.1111/bjd.20865
Volume 186, Issue 1 p. e81-e81
?? T ????? (CTCL) ????????, ??? T ?? (?????) , ??????Mogamulizumab ??????? CTCL ????, ????????????? Mogamulizumab ???? (MAR) ???????MAR ???????, ??? CTCL ??????????, ?????????, ???? 24 ?? 2018 ? Mogamulizumab ?????????????????????????? CTCL ????????
??????????????
doi : 10.1111/bjd.20866
Volume 186, Issue 1 p. e82-e82
??????, ?????????????????????????“???”, ??????????????????????????????, ?????????????, ??????
